Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I)
The resilience of high-grade gliomas (HGGs) against conventional chemotherapies is due to their heterogeneous genetic landscape, adaptive phenotypic changes, and immune escape mechanisms. Innovative immunotherapies have been developed to counteract the immunosuppressive capability of gliomas. Nevert...
Main Authors: | Alice Giotta Lucifero, Sabino Luzzi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Brain Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3425/11/3/386 |
Similar Items
-
Against the Resilience of High-Grade Gliomas: Gene Therapies (Part II)
by: Alice Giotta Lucifero, et al.
Published: (2021-07-01) -
CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors
by: Anna C. Filley, et al.
Published: (2018-10-01) -
The role of CMV in glioblastoma and implications for immunotherapeutic strategies
by: Maryam Rahman, et al.
Published: (2019-01-01) -
Current Immunotherapeutic Strategies for the Treatment of Glioblastoma
by: Mark Dapash, et al.
Published: (2021-09-01) -
NK Cell-Based Glioblastoma Immunotherapy
by: Irene Golán, et al.
Published: (2018-12-01)